HLA
EPZM

Hamilton Lane Advisors’s Epizyme, Inc EPZM Stock Holding History

Hamilton Lane Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-24,673
Closed -$310K – 61
2019
Q2 		$310K Buy
+24,673
New +$317K 0.15% 39
2014
Q4 		– Sell
-16,982
Closed -$460K – 67
2014
Q3 		$460K Buy
+16,982
New +$528K 0.15% 42

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Hamilton Lane Advisors's EPZM Position: Q3 2019 in Review

Hamilton Lane Advisors sold out of Epizyme, Inc (EPZM) in Q3 2019, closing a stake of 24,673 shares — an estimated $310K sold.

Hamilton Lane Advisors first reported a position in EPZM in Q3 2014 and held it in 2 quarters. The position peaked at $460K in Q3 2014. 115 funds tracked by Wall St. Rank hold EPZM as of Q3 2019.

  • Hamilton Lane Advisors reported no remaining Epizyme, Inc position as of Q3 2019 after selling out during the quarter.
  • Hamilton Lane Advisors sold 24,673 Epizyme, Inc shares in Q3 2019, an estimated $310K.
  • Hamilton Lane Advisors first reported a position in Epizyme, Inc in Q3 2014 and held it in 2 quarters.
  • Hamilton Lane Advisors's Epizyme, Inc position peaked at $460K in Q3 2014.
  • 115 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2019.

Based on Hamilton Lane Advisors's 13F filing for Q3 2019, filed 13 Nov 2019.